Lenabasum

Unassigned

New Medicines

Systemic sclerosis (scleroderma)

Information

JBT-101; JBT101; ajulemic acid
Corbus Pharmaceuticals
Corbus Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Cannabinoid CB2 receptor agonist without psychoactive properties that inibits fibrosis
Scleroderma is a complex, multi-system disease with significant risk of serious complications. It is uncommon, and incidence and prevalence of scleroderma varies widely around the world [2]. UK current incidence is 3.7 per million and prevalence 31-88 per million, with peak age of onset of 40 to 50 years [3].
Systemic sclerosis (scleroderma)
Oral